Trial Profile
Special Investigation For Non-HIV Patients Of Mycobutin (Regulatory Post Marketing Commitment Plan)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Mar 2019
Price :
$35
*
At a glance
- Drugs Rifabutin (Primary)
- Indications Mycobacterial infections; Tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 23 Aug 2016 Status changed from active, no longer recruiting to completed.
- 29 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 Jul 2016, according to ClinicalTrials.gov record.
- 29 Mar 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jul 2016, according to ClinicalTrials.gov record.